Cangrelor is a P2Y12 inhibitor under investigation as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix) which is a prodrug cangrelor is an active drug not requiring metabolic conversion.Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009.
This page contains content from the copyrighted Wikipedia article "Cangrelor"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
